Dual blocade of the renin–angiotensin–aldosterone: does it always slow the progression of kidney disease?

Andrzej Więcek; Teresa Nieszporek; Miłosz Zarzecki

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Contact Instructions for authors

2/2010
vol. 13

Send email

Copy url:

abstract:

Dual blocade of the renin–angiotensin–aldosterone: does it always slow the progression of kidney disease?

Andrzej Więcek

,

Teresa Nieszporek

,

Miłosz Zarzecki

Przew Lek 2010; 2: 40-45

Online publish date: 2010/03/24

View full text Get citation

The RAS system has an important role in progression of chronic kidney disease. The inhibition of this system either with an ACE-I or ARB has been shown in clinical trails to be beneficial for renal protection. Dual blockade therapy of the RAS system (ACE-I and ARB) seems to have some benefit on blood pressure reduction, proteinuria and morbidity and mortality. However the results of recently published ONTARGET study has shown that ARB such as telmisartan is as effective as the ACE-I ramipril in preventing cardiovascular events in high risk patients. The combination of the two drugs has not shown benefits in renal outcomes. The decision whether to initiate dual RAS blockade for an individual patient, therefore requires careful assessment of their risk of renal progression.

Dual blocade of the renin–angiotensin–aldosterone: does it always slow the progression of kidney disease?

Andrzej Więcek , Teresa Nieszporek , Miłosz Zarzecki

Andrzej Więcek

,

Teresa Nieszporek

,

Miłosz Zarzecki